OTC Markets OTCPK - Delayed Quote USD

Evotec SE (EVOTF)

8.27

0.00

(0.00%)

At close: January 29 at 3:00:00 PM EST

Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology ...

ACCESS Newswire 9 days ago

EVO

EVOTF
0.00%
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from academic institutions into novel ...

ACCESS Newswire last month

EVO

EVOTF
0.00%
Sector Update: Health Care Stocks Rise in Afternoon Trading

Health care stocks were higher in Friday afternoon trading, with the NYSE Health Care Index and the

PREMIUM
MT Newswires 2 months ago

APLT

EVT.DE
Evotec Announces Change in Management Board

Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024 Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; ...

ACCESS Newswire 2 months ago

EVO

EVOTF
0.00%
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Halozyme withdraws its proposal to acquire Evotec for 11 euro per share in cash. The company maintains its 2024 revenue guidance. Shares up.

Zacks 2 months ago

HALO

EVT.DE
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share in cash, implying a fully diluted equity value of 2.0 billion euro. This move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said. In addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling cont

Benzinga 2 months ago

HALO

EVT.DE
Comment on Withdrawn Non-Binding Offer

Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding ...

ACCESS Newswire 2 months ago

EVO

EVOTF
0.00%
Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal

Investing.com - Shares of Halozyme Therapeutics (NASDAQ:HALO) surged 12% at $51.2 before the opening bell on Friday after the company withdrew its €2 billion ($2.10 billion) proposal to acquire German drug developer Evotec.

Investing.com 2 months ago

HALO

EVT.DE
Halozyme withdraws $2.1 billion buyout offer for German drug developer Evotec

(Reuters) -Halozyme Therapeutics has pulled its proposal to buy Evotec SE for 2 billion euros ($2.09 billion) as the German drug developer was unwilling to engage in discussions, the U.S. firm said on Friday. Shares of Halozyme rose 4.70% to $47.80, while the U.S.-listed stock of Evotec tumbled 19.63% to $4.30. "To date, Evotec has been unwilling to engage with us to explore a potential combination, and a company spokesperson has publicly commented that its goal is to remain an independent company," said Halozyme CEO Helen Torley.

Reuters 2 months ago

HALO

EVT.DE
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion.

PR Newswire 2 months ago

EVO

EVOTF
0.00%
HALO
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.

BioPharma Dive 2 months ago

HALO

EVT.DE

ARGX
Is Evotec SE (EVO) the Best German Stock to Buy Now?

We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where Evotec SE (NASDAQ:EVO) stands against the other German stocks. In Germany, the economic growth is based on industry. According to Deutschland.de, Germany’s manufacturing industry contributed 26.6% to the country’s gross […]

Insider Monkey 2 months ago

EVT.DE
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. In a presentation posted on its investor relations website, Halozyme highlights how its proposed combination with Evotec would create a leading global innovative pharma services company that would deliver significant value to all stakeholders.

PR Newswire 2 months ago

HALO

EVO

EVOTF
0.00%
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

On Thursday, Halozyme Therapeutics, Inc. (NASDAQ:HALO) submitted a non-binding proposal to Evotec SE (NASDAQ:EVO) to acquire the German company for 11.00 euros per share in cash, implying a fully diluted equity value of 2.0 billion euros (around $2.11 billion). The proposal represents a premium of 109% to Evotec’s undisturbed share price on October 15, 2024, the day before Triton Partners’ initial accumulation of Evotec shares. Evotec offers drug discovery and development services to several bio

Benzinga 2 months ago

EVT.DE

HALO
Halozyme Submits $2.11 Billion Acquisition Offer For Evotec

Halozyme Submits $2.11 Billion Acquisition Offer For Evotec

PREMIUM
MT Newswires 2 months ago

HALO

EVT.DE
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid

Investing.com -- Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to enhance its capabilities in drug discovery and development.

Investing.com 2 months ago

EVT.DE

HALO
Halozyme bids for Evotec; BeiGene gets a new name

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first Lyfgenia revenue and Leerink built up its M&A team.

BioPharma Dive 2 months ago

HALO

EVT.DE

BGNE
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) ("Evotec") to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. The proposal represents a premium of 109% to Evotec's undisturbed share price on October 15, 2024, the day prior to Triton Partners' initial accumulation of Evotec shares, and a premium of 7

PR Newswire 2 months ago

HALO

EVO

EVOTF
0.00%
Evotec Third Quarter 2024 Earnings: Misses Expectations

Evotec ( ETR:EVT ) Third Quarter 2024 Results Key Financial Results Revenue: €184.9m (down 5.8% from 3Q 2023). Net...

Simply Wall St. 2 months ago

EVO

EVOTF
0.00%
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal

Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The private equity firm Triton Partners is reportedly considering acquiring Evotec, Bloomberg reported, citing people familiar with the matter. In an SEC filing, Evotec reported that Triton had acquired a 9.99% stake in the company via several open-market transactions. The company offers drug discovery and development services to several biotech and pharmaceutical companies. A

Benzinga 2 months ago

EVT.DE

Performance Overview

Return	EVOTF	DAX P
YTD	-10.30%	+9.13%
1-Year	-48.31%	+28.25%
3-Year	-78.97%	+41.83%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Evotec SE (EVOTF)

Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Sector Update: Health Care Stocks Rise in Afternoon Trading

Evotec Announces Change in Management Board

HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Comment on Withdrawn Non-Binding Offer

Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal

Halozyme withdraws $2.1 billion buyout offer for German drug developer Evotec

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

Is Evotec SE (EVO) the Best German Stock to Buy Now?

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

Halozyme Submits $2.11 Billion Acquisition Offer For Evotec

Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid

Halozyme bids for Evotec; BeiGene gets a new name

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

Evotec Third Quarter 2024 Earnings: Misses Expectations

Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal

Performance Overview